Evidence map›Paper›PMID 40241752›Full record

ArticleiScience2025

CRISPR/Cas9-mediated SHP-1-knockout T cells combined with simvastatin enhances anti-tumor activity in humanized-PDX HCC model.

Huaping Liu, Wu Ge, Xiaoping Yu, Jianwei Luo, Juan Zhang, Min Yang, Lu Cao, Yangnan Zhang, Ruike Wang, Cejun Yang and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Huaping LiuDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wu GeDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiaoping YuDepartment of Radiology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Jianwei LuoDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Juan ZhangDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Min YangDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lu CaoDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yangnan ZhangXiangya School of Medicine, Central South University, Changsha, Hunan, China.
Ruike WangXiangya School of Medicine, Central South University, Changsha, Hunan, China.
Cejun YangDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Pei LiDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Mengyu TianDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
XiaoPei PengDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lei PengDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Di WuDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Muqi LiuDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Qi LiangDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Shengwang ZhangDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wei LiDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Pengfei RongDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Hailan LiDepartment of Radiology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University.
Xiaoqian MaDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.
Wei WangDepartment of Radiology, the 3 Xiangya Hospital of Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) resists immunotherapy due to its immunosuppressive microenvironment. Sarcoma homology 2 domain-containing protein tyrosine phosphatase-1 (SHP-1) inhibits T cell receptor signaling, and its pharmacological inhibition is limited by poor selectivity and membrane permeability. Here, we generated CRISPR-edited SHP-1-knockout (KO) CD8

Indexed as

Biological sciencesCancerCancer systems biologyNatural sciencesSystems biology

Identifiers

PMID40241752
PMCPMC12003012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.